Thelansis Knowledge Partners

Friday, 6 August 2021

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Cushing’s Syndrome (CS)

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cushing’s syndrome can be caused by overuse of cortisol medication, as seen in the treatment of chronic asthma or rheumatoid arthritis (iatrogenic Cushing’s syndrome), excess production of cortisol from a tumor in the adrenal gland or elsewhere in the body (ectopic Cushing’s syndrome) or a tumor of the pituitary gland secreting adrenocorticotropic hormone (ACTH) which stimulates the over-production of cortisol from the adrenal gland (Cushing’s disease).

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, pituitary ACTH-dependent Cushing's causes 68% to 72% of Cushing's syndrome. The reported incidence was 1.53 to 2.43 per million per year in European population-based studies and 6.3 to 7.3 per million person-years in the United States

Competitive landscape of Cushing’s Syndrome (CS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cushing’s Syndrome (CS) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cushing’s Syndrome (CS) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Partner Phase
1 Korlym Corcept Therapeutics Inc. N/A Approved
2 Signifor Recordati SpA Novartis Approved
3 Ketoconazole HRA Pharma N/A Approved in Europe
4 Cytadren Novartis AG N/A Withdrawn from Market
5 Osilodrostat Recordati SpA Novartis NDA
6 Recorlev Strongbridge Biopharma plc N/A III
7 Relacorilant Corcept Therapeutics Inc. N/A III
8 Mifedren HRA Pharma N/A II/III
9 Nevanimibe Millendo Therapeutics, Inc. N/A II
10 Lysodren HRA Pharma N/A Investigator Initiated
11 Seliciclib Cyclacel Pharmaceuticals, Inc. ManRos Therapeutics Investigator Initiated
12 COR-005 Strongbridge Biopharma plc Evotec Development Outside U.S.
13 HTL0030310 Sosei Co., Ltd N/A Development Outside U.S.
14 ACTH Antagonist (Crinetics) Crinetics Pharmaceuticals, Inc. N/A Preclinical
15 Anti-ACTH XOMA Corporation N/A Preclinical
16 AP102 Amryt Pharma plc N/A Preclinical
17 BIM23B065 Ipsen SA N/A Preclinical
18 Steroidogenic factor-1 (SF-1) Antagonists Orphagen Pharmaceuticals N/A Preclinical

Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030

Indication name: Charcot-Marie-Tooth (CMT)

Charcot-Marie-Tooth (CMT) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Charcot-Marie-Tooth disease (CMT) is one of a group of disorders that cause damage to the peripheral nerves—the nerves that transmit information and signals from the brain and spinal cord to and from the rest of the body, as well as sensory information such as touch back to the spinal cord and brain. CMT is caused by mutations in genes that support or produce proteins involved in the structure and function of either the peripheral nerve axon or the myelin sheath. More than 40 genes have been identified in CMT, with each gene linked to one or more types of the disease. In addition, multiple genes can be linked to one type of CMT. More than half of all cases of CMT are caused by a duplication of the PMP22 gene on chromosome 17.

Classification-

There are different types of CMT disease such as; CMT1, CMT2, CMT3 (Dejerine-Sottas disease), CMT4, CMTX1 (also called CMT X, Type 1)

Epidemiology-

CMT is one of the most common inherited neurological disorders, affecting an estimated 148,000 individuals in the United States and > 3.2 million people worldwide.

Competitive landscape of Acromegaly includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Charcot-Marie-Tooth (CMT) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Charcot-Marie-Tooth (CMT) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Partner Phase
1 PXT3003 Pharnext SA Tasly Pharmaceutical Group III
2 NT-3 Gene Therapy Nationwide Children’s Hospital Sarepta Therapeutics I/II
3 IFB-088 InFlectis BioScience N/A I
4 Engensis Helixmith Co., Ltd. Northland Status to confirm
5 CMT4J Disease Therapy Neurogene Inc. N/A Preclinical
6 Ricolinostat Bristol-Myers Squibb Company Regenacy Preclinical

Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Acromegaly

Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. Acromegaly may also cause thickening of the soft tissues of the body, including the heart, lips, and tongue. When the disease affects children prior to the end of puberty, excess growth hormone can lead to accelerated growth and tall stature, known as gigantism. Acromegaly may be caused by the ineffective control of growth hormone-secreting cells by the hypothalamus (a gland in the brain that regulates hormone secretions).

In rare cases, non-pituitary tumors in the pancreas, lungs or adrenal glands may cause acromegaly. In some cases, acromegaly may occur as part of certain genetic syndromes including multiple endocrine neoplasia type 1, familial isolated pituitary adenoma, the Carney complex and McCune-Albright syndrome. X-linked acrogigantism causes gigantism and is due to microduplications of segments of the X chromosome.

Epidemiology-
About 3 to 14 of every 100,000 people have been diagnosed as having acromegaly.

Competitive landscape of Acromegaly includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Acromegaly 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Acromegaly market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Stage
1 Sandostatin Novartis AG Approved (Generic Competition)
2 Sandostatin LAR Novartis AG Approved
3 Signifor Recordati SpA Approved
4 Somatuline Autogel Ipsen SA Approved
5 Somavert Nektar Therapeutics Approved
6 CAM2029 Novartis AG III
7 Mycapssa Chiasma, Inc III
8 ATL1103 Antisense Therapeutics, Ltd. II
9 COR-005 Strongbridge Biopharma plc II
10 CRN00808 Crinetics Pharmaceuticals, Inc. II
11 IONIS-GHR-LRx Ionis Pharmaceuticals, Inc. II
12 DP1038 Dauntless Pharmaceuticals, Inc. I
13 Glide Octreotide Enesi Pharma Limited I
14 ONO-5788 Ono Pharmaceutical Company, Ltd. I
15 Q-Octreotide Midatech Pharma PLC I
16 ITF-2984 Italfarmaco S.p.A. Development Outside U.S.
17 AP102 Amryt Pharma plc Preclinical
18 AQST-305 Aquestive Therapeutics, Inc Preclinical

Alpha-1 antitrypsin deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency (AATD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Alpha-1 antitrypsin deficiency (Alpha-1 or AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. AAT is mainly produced by the liver, and its primary function is to protect the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3)

Epidemiology-

According to Thelansis disease modeling data and literature review estimated ~78000 patients with AATD in the United States in the year 2020.

Competitive landscape of Alpha-1 antitrypsin deficiency includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Alpha-1 antitrypsin deficiency 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Alpha-1 antitrypsin deficiency market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Stage
1 Aerosolized, Recombinant Alpha 1-Antitrypsin Arriva Pharmaceuticals, Inc. Phase 2
2 Alpha-1 15% Grifols Therapeutics LLC Phase 2
3 ADVM-043 Adverum Biotechnologies, Inc. Phase 2
4 Alpha 1-Antitrypsin Kamada, Ltd. Phase 3
5 INBRX-101/rhAAT-Fc Inhibrx, Inc. Phase 1
6 ARO-AAT Injection Arrowhead Pharmaceuticals Phase 2
7 belcesiran Dicerna Pharmaceuticals, Inc. Phase 2
8 rAAV1-CB-hAAT Applied Genetic Technologies Corp Phase 2
9 VX-864 Vertex Pharmaceuticals Incorporated Phase 2
10 ZF874 Z Factor Limited Phase 1
11 Carbamazepine (Tegretol XR) Novartis Phase 22

Thursday, 5 August 2021

Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Mesothelioma

Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Mesothelioma is a type of cancer that develops in the lining that covers the outer surface of some of the body's organs. It's usually linked to asbestos exposure. Mesothelioma mainly affects the lining of the lungs (pleural mesothelioma), although it can also affect the lining of the tummy (peritoneal mesothelioma), heart, or testicles.

The four types of mesothelioma are identified by the location in the body where tumors develop. Pleural and peritoneal types of mesothelioma are the most common. Pericardial and testicular mesothelioma accounts for less than 2% of cases combined.

Epidemiology-

According to Thelansis disease modeling data and literature review estimated approximately 3350 cases of malignant mesothelioma are diagnosed annually. In the absence of occupational exposure to asbestos, the incidence is 0.1-0.25 per 100,000 population in both sexes. The risk of mesothelioma is increased in polluted areas by 2-10 fold compared with non-polluted areas. In patients with malignant mesothelioma in the United States, 80% have been exposed to asbestos.

Competitive landscape of Mesothelioma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Mesothelioma 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.
Mesothelioma market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Stage
1 ONCOFID®-P Fida Farmaceutici Phase 2
2 MTG201 Momotaro-Gene Inc. Phase 2
3 MesoPher Amphera BV Phase 3
4 YS110 Kissei Pharmaceutical Co., Ltd. Phase 2
5 IAG933 Novartis Pharmaceuticals Phase 1
6 Expansion Cohort Oncovir, Inc. Phase 1
7 BBI608 Sumitomo Dainippon Pharma Co., Ltd. Phase 2
8 Pembrolizumab Merck Sharp & Dohme Corp. Phase 1
9 BAY2287411 Bayer Phase 1
10 Nivolumab Injection Bristol-Myers Squibb Phase 3
11 rAd-IFN Trizell Ltd Phase 3
12 Pemetrexed NovoCure Ltd. Phase 2
13 Immunotherapy plus chemotherapy Aduro Biotech, Inc. Phase 1
14 HMPL-453 Hutchison Medipharma Limited Phase 2
15 ONCOS-102 Theradex Phase 2
16 WT-1-vaccine Montanide + GM-CSF Sellas Life Sciences Group Phase 2
17 ADI-PEG 20 plus Pem Cis Polaris Group Phase 3
18 Vorinostat Merck Sharp & Dohme Corp. Phase 3
19 Tazemetostat Epizyme, Inc. Phase 2
20 NGR-hTNF plus Best Investigator's Choice (BIC) AGC Biologics S.p.A. Phase 3
21 Tremelimumab MedImmune LLC Phase 2
22 Avelumab Pfizer Phase 2
23 pemetrexed, cisplatin and CBP501 CanBas Co. Ltd. Phase 2
24 SAR444245 Sanofi Phase 2
25 Vinorelbine Pierre Fabre Laboratories Phase 2
26 Durvalumab PrECOG, LLC. Phase 2
27 Trabectedin PharmaMar Phase 2
28 Bevacizumab and Atezolizumab Hoffmann-La Roche Phase 3
29 cyclophosphamide Atara Biotherapeutics Phase 1
30 Alisertib Millennium Pharmaceuticals, Inc. Phase 2
31 MCY-M11 MaxCyte, Inc. Phase 1
32 VT3989 Vivace Therapeutics, Inc Phase 1
33 αPD1-MSLN-CAR T cells Shanghai Cell Therapy Group Co.,Ltd Phase 1
34 GL-ONC1 Genelux Corporation Phase 1
35 APG-2449 Ascentage Pharma Group Inc. Phase 1
36 S-488210 Shionogi Inc. Phase 1
37 SG001 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 1
38 SCH 721015 Biogen Phase 1
39 SGN-CD228A Seagen Inc. Phase 1
40 INCB001158 Incyte Corporation Phase 2
41 AdV-tk + valacyclovir Candel Therapeutics, Inc. Phase 1
42 gavo-cel TCR2 Therapeutics Phase 2
43 NGM707 NGM Biopharmaceuticals, Inc Phase 2
44 INBRX-109 Inhibrx, Inc. Phase 1
45 VMD-928 VM Oncology, LLC Phase 1
46 CB-839 Calithera Biosciences, Inc Phase 1
47 SO-C101 Sotio a.s. Phase 1
48 QBS10072S Quadriga Biosciences, Inc. Phase 1
49 IOA-244 iOnctura Phase 1
50 ASTX295 Astex Pharmaceuticals, Inc. Phase 2

Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Cystic fibrosis

Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Cystic fibrosis is an autosomal recessive disease caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is an ion channel protein that transports chloride ions across the membranes of cells that line airways, glands, and the digestive tract.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the prevalence of Cystic fibrosis in a range of 0.72 to 0.76 per 10,000 in the 27 EU countries, whereas prevalence is reported to be 0.81 in the United States.

Competitive landscape of Cystic fibrosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cystic fibrosis 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cystic fibrosis market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Stage
1 VX-121 & VX-561 Vertex Pharmaceuticals Incorporated Phase 3
2 Galicaftor AbbVie Phase 2
3 P-1037 Parion Sciences Phase 2
4 MP-376 Horizon Pharma USA, Inc. Phase 3
5 AIR DNase Protalix Phase 1
6 Ultrase® MT20 Forest Laboratories Phase 3
7 Cavosonstat Nivalis Therapeutics, Inc. Phase 2
8 BI 443651 Boehringer Ingelheim Phase 1
9 ALX-009 Alaxia SAS Phase 1
10 POL6014 Santhera Pharmaceuticals Phase 2
11 Cavosonstat Nivalis Therapeutics, Inc. Phase 2
12 ELX/TEZ/IVA Vertex Pharmaceuticals Incorporated Phase 3
13 Ataluren (PTC124®) PTC Therapeutics Phase 3
14 Liposomal amikacin for inhalation Insmed Incorporated Phase 3
15 OligoG DPI AlgiPharma AS Phase 2
16 QR-010 ProQR Therapeutics Phase 1
17 CHF 6333 Chiesi Farmaceutici S.p.A. Phase 1
18 Cysteamine NovaBiotics Ltd. Phase 2
19 AZLI Gilead Sciences Phase 3
20 Vancomycin inhalation powder Savara Inc. Phase 3
21 TOBI Novartis Pharmaceuticals Phase 3
22 AZLI Gilead Sciences Phase 3
23 MRT5005 Translate Bio, Inc. Phase 2
24 MS1819-SD AzurRx SAS Phase 2
25 SPI-1005 Sound Pharmaceuticals, Incorporated Phase 2
26 N91115 Nivalis Therapeutics, Inc. Phase 1
27 Nitric oxide Beyond Air Inc. Phase 2
28 QR-010 ProQR Therapeutics Phase 2
29 AIR DNase™ Protalix Phase 2
30 EUR-1008 (APT-1008) Forest Laboratories Phase 3

Essential thrombocytosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Essential thrombocytosis

Essential thrombocytosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Essential thrombocytosis (primary thrombocythemia) is a nonreactive, chronic myeloproliferative disorder in which sustained megakaryocyte proliferation leads to an increase in the number of circulating platelets. Mutations in JAK2, CALR, or MPL are found in approximately 90% of patients with essential thrombocytosis.

Essential thrombocytosis is characterized by the following:
Platelet count > 450,000/µL
Megakaryocytic hyperplasia
Splenomegaly
A clinical course complicated by thrombotic or hemorrhagic episodes or both.

Epidemiology-
According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the incidence of Essential thrombocytosis is between a range of 0.42 to 1.68 per 100,000 in the EU countries, whereas incidence is reported much higher between a range of 2.25 to 2.37 per 100,000 in the United States.

Competitive landscape of Essential thrombocytosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Essential thrombocytosis 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Essential thrombocytosis market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

S. No Asset Company Stage
1 Ropeginterferon alfa-2b PharmaEssentia Phase 3
2 Ropeginterferon alfa-2b Medpace, Inc. Phase 3
3 IMG-7289 Imago BioSciences,Inc. Phase 2
4 Pacritinib PSI CRO Phase 3
5 Anagrelide retard AOP Orphan Pharmaceuticals AG Phase 3
6 anagrelide hydrochloride Takeda Phase 2
7 SPD422 (anagrelide hydrochloride) Shire Phase 3
8 Imetelstat Geron Corporation Phase 2
9 LY573636-sodium Eli Lilly and Company Phase 1
10 NS-018 NS Pharma, Inc. Phase 2
11 Pacritinib CTI BioPharma Phase 2
12 PXS-5505 Pharmaxis Phase 2
13 itacitinib Incyte Corporation Phase 2
14 PU-H71 Samus Therapeutics, Inc. Phase 1
15 KRT-232 Kartos Therapeutics, Inc. Phase 3
16 RG7388 Roche Pharma AG Phase 1
17 AZD1480 AstraZeneca Phase 1
18 INC424 Novartis Pharmaceuticals Phase 3
19 MMB Sierra Oncology, Inc. Phase 2
20 SAR302503 Sanofi Phase 2
21 Simtuzumab Gilead Sciences Phase 2
22 PEGASYS Ronald Hoffman Phase 3
23 Anagrelide CR Galena Biopharma, Inc. Phase 2
24 Selinexor Karyopharm Therapeutics Inc Phase 2
25 APLIDIN (plitidepsin) PharmaMar Phase 2
26 LNK01002 Lynk Pharmaceuticals Co., Ltd Phase 1
27 LY2784544 Eli Lilly and Company Phase 1
28 CPI-0610 Constellation Pharmaceuticals Phase 3
29 givinostat Italfarmaco Phase 2
30 rigosertib Onconova Therapeutics, Inc. Phase 2
31 Luspatercept Celgene Phase 2
32 Ruxolitinib Actuate Therapeutics Inc. Phase 2
33 Navitoclax AbbVie Phase 1
34 TAS1553 Astex Pharmaceuticals, Inc. Phase 1
35 Ruxolitinib Helsinn Healthcare SA Phase 2
36 busulfan Otsuka America Pharmaceutical Phase 2